DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer

• Published in: Clinical epigenetics Vol. 13; no. 1; p. 38
• Main Authors: Goldmann, Torsten, Schmitt, Bernhard, Müller, Julia, Kröger, Maren, Scheufele, Swetlana, Marwitz, Sebastian, Nitschkowski, Dörte, Schneider, Marc A, Meister, Michael, Muley, Thomas, Thomas, Michael, Kugler, Christian, Rabe, Klaus F, Siebert, Reiner, Reck, Martin, Ammerpohl, Ole
• Format: Journal Article
• Language: English
• Published: Germany BioMed Central Ltd 17.02.2021; BioMed Central
• Subjects: Analysis; Apoptosis; Biopsy; Bronchoscopy; Bronchus; Cancer; Cell adhesion & migration; Cluster analysis; CpG islands; Deoxyribonucleic acid; Diagnosis; DNA; DNA methylation; Epigenetics; Genes; Genetic aspects; Genetic research; Genetic testing; Health aspects; Histology; Lung cancer; Lung cancer, Non-small cell; Methylation; Non-small cell lung carcinoma; Patients; Tumors; DNA methylation; Lung cancer; Paired biopsies
• ISSN: 1868-7075; 1868-7083; 1868-7083; 1868-7075
• DOI: 10.1186/s13148-021-01024-6

Lung cancer is the leading cause of cancer-related death in most western countries in both, males and females, accounting for roughly 20-25% of all cancer deaths. For choosing the most appropriate therapy regimen a definite diagnosis is a prerequisite. However, histological characterization of bronchoscopic biopsies particularly with low tumor cell content is often challenging. Therefore, this study aims at (a) determining the value of DNA methylation analysis applied to specimens obtained by bronchoscopic biopsy for the diagnosis of lung cancer and (b) at comparing aberrantly CpG loci identified in bronchoscopic biopsy with those identified by analyzing surgical specimens. We report the HumanMethylation450-based DNA methylation analysis of paired samples of bronchoscopic biopsy specimens either from the tumor side or from the contralateral tumor-free bronchus in 37 patients with definite lung cancer diagnosis and 18 patients with suspicious diagnosis. A differential DNA methylation analysis between both biopsy sites of patients with definite diagnosis identified 1303 loci. Even those samples were separated by the set of 1303 loci in which histopathological analysis could not unambiguously define the dignity. Further differential DNA methylation analyses distinguished between SCLC and NSCLC. We validated our results in an independent cohort of 40 primary lung cancers obtained by open surgical resection and their corresponding controls from the same patient as well as in publically available DNA methylation data from a TCGA cohort which could also be classified with high accuracy. Considering that the prognosis correlates with tumor stage at time of diagnosis, early detection of lung cancer is vital and DNA methylation analysis might add valuable information to reliably characterize lung cancer even in histologically ambiguous sample material.